Viyash prioritises companion-animal deals over debt repayment
Key highlights
- Viyash is reviewing repayment of an India-based loan of about Rs 120 crore.
- Management said the next year could be Viyash’s peak year for acquisitions.
- Companion animals are Viyash’s first acquisition priority.
- Viyash expects its Ambernath companion-animal facility to be ready in the first quarter of the next year.
powered by IRIS

In its earnings call, Viyash said it will prioritise growth capital expenditure and companion-animal acquisitions over immediate debt repayment, while reviewing an India-based loan of about Rs 120 crore. Management said the next year could be its peak year for acquisitions, after which it may revisit repayment and purchases of minority interests.
Know Viyash Scientific inside out
Results, valuation, peers and who's buying, in one view.
Will Viyash repay debt before pursuing acquisitions?
No. Viyash said acquisitions and growth capital expenditure come before immediate debt repayment, although management is assessing whether to repay an India-based loan of about Rs 120 crore. Management said the broader decision remains under debate because an acquisition programme requires financial capacity.
Viyash distinguished routine capital expenditure from acquisition funding in its explanation. Management said it sees no issue in funding capital expenditure, but an acquisition requires a separate decision on whether retaining funds produces a better outcome than prepaying debt. The Rs 120 crore loan is therefore a specific repayment candidate, rather than a disclosed timetable for reducing all debt.
Management described the order of capital allocation as conditional rather than fixed. It said it will assess alternatives over the next one to two years and that the next year may be the peak year for acquisitions. After that period, Viyash may consider debt repayment and the acquisition of remaining minority stakes.
Which acquisitions does Viyash want to pursue first?
Viyash said companion-animal opportunities are its first acquisition priority. Management identified animal health, particularly companion animals, as the area with the most immediate visibility, indicating that its search is focused on products and market access rather than broad expansion of manufacturing capacity.
The company is also considering specialty contract development and manufacturing organisation, or CDMO, opportunities and specialty-product acquisitions. Management said it does not want manufacturing-heavy or “me-too” transactions because Viyash already has a large manufacturing base. It instead cited in-licensing of products and company acquisitions as possible routes to faster growth.
The acquisition preference is linked to the planned companion-animal launch cycle from 2029. Management said several larger products are expected to face patent expiry in major markets around that period, and Viyash is preparing to pursue day-one launches. It did not disclose an acquisition budget, a target company or a committed deal date.
Why is Viyash focused on companion animals?
Viyash is focused on companion animals because management expects better gross margins in that segment and sees product-launch opportunities from 2029. Management said companion animals currently represent about 10% of the relevant business mix, so the segment remains relatively small before any acquisition or future launches.
Management said a suitable acquisition next year could improve companion animals’ contribution, but it did not quantify potential revenue, market share or margin gains. Its strategy is to move from launches of mature products toward launches on the first day of generic entry, which management said involves longer gestation periods and larger upfront investment.
Viyash said animal-health investment has risen from about Rs 10 crore to Rs 12 crore previously to about Rs 40 crore currently. Management cited this increase in future-oriented spending as one reason earnings before interest, tax, depreciation and amortisation, or EBITDA, margins have not expanded. The spending is part of the preparation for products expected to launch around 2029, not a forecast of near-term companion-animal sales.
Got a follow-up? Ask IRIS
How is Viyash preparing for companion-animal launches?
Viyash is building dedicated capacity and arranging alternative supply options for companion-animal launches expected from 2029. Management said companion-animal products differ from human tablets in size and flavour, and therefore require suitable equipment and dedicated production capability. It described its Ambernath facility as central to a fully integrated companion-animal strategy.
Management expects the Ambernath site to be ready in the first quarter of the next year. It said the timing leaves sufficient time before the anticipated 2029 launch window, while noting that it is preparing filings from the new site and other locations in parallel. This approach is intended to prevent construction or inspection timing from restricting product filings.
Viyash is also working with a partner site in Turkey that management expects to become Europe-approved around December or January. The Turkish facility is intended as a backup if a new-site audit is delayed, and management said it would also support launches in Turkey. The company did not disclose production capacity for either the Ambernath or Turkey site.
Which markets are part of Viyash’s animal-health plan?
Viyash said Vietnam is a large farm-animal market and expects it to contribute about Rs 30 lakh to Rs 50 lakh over the next couple of years. Management described Vietnam as a stable, mature farm-animal business rather than a market for large new launches, while saying companion-animal expansion could add to the opportunity.
For companion animals, Viyash is exploring Australia and Canada after completing product development and registrations for Europe. Management said it is seeking to build a front end in those two markets, using European filings and development work as a potential basis for further registrations. No revenue target or launch date was provided for Australia or Canada.
Management described the United States as a longer-term priority rather than an immediate acquisition focus. It said Viyash may give the market greater attention in two to three years, after it has pursued nearer-term opportunities in Europe and other existing markets. Management added that it expects generic penetration in the US companion-animal market, currently about 15% to 20%, to improve over the next three to four years.
What does the plan mean for Viyash’s capital allocation?
Viyash is preserving financial flexibility for targeted product, market-access and specialty transactions rather than announcing an immediate deleveraging programme. The company has identified a Rs 120 crore loan for possible repayment, but management’s stated sequence is growth capital expenditure and acquisitions first, followed by potential repayment and minority-stake purchases.
The company also disclosed a change in employee stock option plan, or ESOP, expense. Management expects ESOP expense of about Rs 148 crore to Rs 149 crore in the current year, followed by about Rs 32 crore in the next year and a stable-state level of about Rs 25 crore thereafter. That cost outlook is separate from acquisition funding, but it forms part of Viyash’s stated financial planning.
Conclusion
Viyash has not ruled out debt repayment, but management has clearly placed companion-animal acquisitions and growth investment ahead of an immediate reduction in borrowings. Its preference is for specialty products, in-licensing and market access rather than manufacturing-led deals, while its Rs 120 crore India-based loan remains under review.
The next item to watch is whether the next year, which management described as a potential peak period for acquisitions, produces a companion-animal transaction or in-licensed products. Operationally, progress at the Ambernath facility in the first quarter of the next year and the Turkey backup route around December or January will indicate readiness for the 2029 launch programme.


